WebPHESGO™ (pertuzumab, trastuzumab, and hyaluronidase-zzxf) injection, for subcutaneous use. PHESGO is a fixed-dose combination of pertuzumab and trastuzumab, HER2/neu …

Phesgo™ (pertuzumab, trastuzumab and hyaluronidase zzxf)

WebPertuzumab, Trastuzumab and Hyaluronidase -zzxf Injection, for Subcutaneous use (Phesgo™) HCPCS Code J9999: Billing Guidelines TUESDAY, AUGUST 25, 2024 ... (PADP) when billed with HCPCS code J9999 - Not otherwise classified, antineoplastic drugs. More. Lurbinectedin for Injection, for Intravenous Use (Zepzelca™) HCPCS Code J9999: Billing ... Web• less than 6 weeks, the maintenance dose of Phesgo 600 mg/600 mg should be administered as soon as possible. Thereafter, continue with the 3-weekly schedule. • 6 weeks or more, a loading dose of Phesgo 1200 mg/600 mg should be re-administered followed by maintenance dose of Phesgo 600 mg/600 mg every 3 weeks thereafter. dashiell construction / engineering

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

WebThe FDA product label includes the following information: other, 1.1 early breast cancer (ebc), 1.2 metastatic breast cancer (mbc), 2.1 patient selection, 2.2 important dosage and administration information, 2.3 recommended doses and schedu WebPhesgo 1200 mg/600 mg/30,000 units (providing 1200 mg pertuzumab, 600 mg trastuzumab and 30,000 units hyaluronidase per 15 mL) single-dose vials: 50242-0245-xx Phesgo 600 mg/600 mg/20,000 units (providing 600 mg pertuzumab, 600 mg trastuzumab and 20,000 units hyaluronidase per 10 mL) single-dose vials: 50242-0260-xx VII. … WebMay 2, 2024 · HCPCS Code: J9316 – Injection, pertuzumab, trastuzumab, and hyaluronidase-zzxf, per 10 mg; 1 billable unit = 10 mg NDC(s): Phesgo (1,200 mg pertuzumab, 600 mg trastuzumab, and 30,000 units hyaluronidase per 15 mL) single-dose vial: 50242-0245-xx Phesgo (600 mg pertuzumab, 600 mg trastuzumab, and 20,000 units … dashiell construction